Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Common Equity (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Common Equity for 13 consecutive years, with $602.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 20.11% to $602.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $602.7 million, a 20.11% decrease, with the full-year FY2025 number at $602.7 million, down 20.11% from a year prior.
  • Common Equity was $602.7 million for Q4 2025 at Madrigal Pharmaceuticals, down from $625.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $857.1 million in Q2 2024 to a low of $10.7 million in Q3 2022.
  • A 5-year average of $397.8 million and a median of $265.6 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 95.46% in 2022, then surged 3392.99% in 2024.
  • Madrigal Pharmaceuticals' Common Equity stood at $196.1 million in 2021, then increased by 0.65% to $197.4 million in 2022, then surged by 105.35% to $405.3 million in 2023, then surged by 86.11% to $754.4 million in 2024, then dropped by 20.11% to $602.7 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Common Equity are $602.7 million (Q4 2025), $625.7 million (Q3 2025), and $696.0 million (Q2 2025).